Pegylated filgrastim — Competitive Intelligence Brief

Pegylated filgrastim (Pegylated filgrastim) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Granulocyte colony-stimulating factor (G-CSF) analog. Area: Oncology.

phase 3 Granulocyte colony-stimulating factor (G-CSF) analog G-CSF receptor (GCSFR) Oncology Small molecule

Target snapshot

Pegylated filgrastim (Pegylated filgrastim) — Merck Sharp & Dohme LLC. Pegylated filgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in chemotherapy patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegylated filgrastim TARGET	Pegylated filgrastim	Merck Sharp & Dohme LLC	phase 3	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Filgrastim-sndz	Filgrastim-sndz	M.D. Anderson Cancer Center	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Neulasta® (pegfilgrastim)	Neulasta® (pegfilgrastim)	Amgen	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
PEG-G-CSF	PEG-G-CSF	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Pegfilgrastim-Cbqv	Pegfilgrastim-Cbqv	Coherus Oncology, Inc.	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Grastofil®	Grastofil®	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	phase 3	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (CSF3R)
PEG-rhG-GSF	PEG-rhG-GSF	The First Affiliated Hospital with Nanjing Medical University	phase 3	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Granulocyte colony-stimulating factor (G-CSF) analog class)

1. Amgen · 1 drug in this class
2. Coherus Oncology, Inc. · 1 drug in this class
3. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 1 drug in this class
4. M.D. Anderson Cancer Center · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Sanofi · 1 drug in this class
7. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class